poisar

Stock

Palvella Therapeutics, Inc. PVLA

$150.14-2.82%

Overview

PVLA market data

Price History

PVLA price chart · 1M
O
156.04
H
156.04
L
150.00
C
150.14
Vol
11,662.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$156.04
Previous Close
$154.49
Day High
$156.04
Day Low
$150.00
52 Week High
$160.05
52 Week Low
$100.19
7 Day Return
+5.46%
30 Day Return
+5.29%
90 Day Return
+27.11%
1 Year Return
+22.48%
Daily Notional Volume
$1.8M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$7.62
Diluted earnings per share over the trailing twelve months.
Beta
-0.23
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-39.7%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$49.13 – $161.38
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $2.2B · P/B 44.27 · P/S 54.74.

Company News

6 captured
Full Transcript: Palvella Therapeutics Q2 2026 Earnings CallBenzinga · Aug 4, 2026, 1:52 PM
Palvella Therapeutics Q2 EPS $(1.52) Misses $(1.14) EstimateBenzinga · Aug 4, 2026, 11:30 AM
8-K filing — PALVELLA THERAPEUTICS, INC. (PVLA)SEC EDGAR · Aug 4, 2026, 11:30 AM
Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On TuesdayBenzinga · Jul 21, 2026, 2:37 PM
Palvella Therapeutics Submits First Module Of Rolling NDA To FDA Seeking Approval Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic MalformationsBenzinga · Jun 29, 2026, 11:40 AM
Palvella Therapeutics Announces FDA Rolling Review Of Its New Drug Application For Qtorin Rapamycin For The Treatment Of Microcystic Lymphatic MalformationsBenzinga · Jun 22, 2026, 11:40 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock